USA - NASDAQ:OKYO - GG00BMFG5F62 - Common Stock
The current stock price of OKYO is 2.13 USD. In the past month the price decreased by -6.99%. In the past year, price increased by 110.89%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.85 | 390.07B | ||
AMGN | AMGEN INC | 12.6 | 147.89B | ||
GILD | GILEAD SCIENCES INC | 14.5 | 139.29B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.85 | 99.26B | ||
REGN | REGENERON PHARMACEUTICALS | 12.83 | 62.06B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.21B | ||
ARGX | ARGENX SE - ADR | 79.22 | 44.94B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.79 | 39.49B | ||
INSM | INSMED INC | N/A | 30.60B | ||
NTRA | NATERA INC | N/A | 24.08B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.59B | ||
BIIB | BIOGEN INC | 9.05 | 21.24B |
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
OKYO PHARMA LTD
Floor 4, 14/15 Conduit St
London GB
Employees: 4
Phone: 442074952379
The current stock price of OKYO is 2.13 USD. The price increased by 1.43% in the last trading session.
The exchange symbol of OKYO PHARMA LTD is OKYO and it is listed on the Nasdaq exchange.
OKYO stock is listed on the Nasdaq exchange.
8 analysts have analysed OKYO and the average price target is 10.2 USD. This implies a price increase of 378.87% is expected in the next year compared to the current price of 2.13. Check the OKYO PHARMA LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OKYO PHARMA LTD (OKYO) has a market capitalization of 46.37M USD. This makes OKYO a Nano Cap stock.
OKYO PHARMA LTD (OKYO) currently has 4 employees.
OKYO PHARMA LTD (OKYO) has a support level at 2.12. Check the full technical report for a detailed analysis of OKYO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OKYO does not pay a dividend.
OKYO PHARMA LTD (OKYO) will report earnings on 2025-12-22.
OKYO PHARMA LTD (OKYO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.34).
The outstanding short interest for OKYO PHARMA LTD (OKYO) is 0.21% of its float. Check the ownership tab for more information on the OKYO short interest.
ChartMill assigns a technical rating of 3 / 10 to OKYO. When comparing the yearly performance of all stocks, OKYO is one of the better performing stocks in the market, outperforming 91.28% of all stocks.
Over the last trailing twelve months OKYO reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 79.21% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -127.98% | ||
ROE | N/A | ||
Debt/Equity | N/A |
8 analysts have analysed OKYO and the average price target is 10.2 USD. This implies a price increase of 378.87% is expected in the next year compared to the current price of 2.13.